Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2000 1
2005 1
2012 1
2014 1
2016 3
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for F. holahan
Your search for F. kolahan retrieved no results
Adrenomedullary function during cognitive testing in attention-deficit/hyperactivity disorder.
Anderson GM, Dover MA, Yang BP, Holahan JM, Shaywitz SE, Marchione KE, Hall LM, Fletcher JM, Shaywitz BA. Anderson GM, et al. J Am Acad Child Adolesc Psychiatry. 2000 May;39(5):635-43. doi: 10.1097/00004583-200005000-00018. J Am Acad Child Adolesc Psychiatry. 2000. PMID: 10802982 Free article. Review.
RESULTS: Substantially lower (mean +/- SE) urinary EPI excretion was observed in the ADHD-inattentive subtype (n = 71) compared with the control group (200 +/- 22 versus 278 +/- 24 ng/hr/m2; F = 5.99, p = .015, critical alpha = .017). No diagnostic group differences were s …
RESULTS: Substantially lower (mean +/- SE) urinary EPI excretion was observed in the ADHD-inattentive subtype (n = 71) compared with the con …
Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).
Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Holahan M, O'Malley S, Purcell M, Riffel K, Li J, Balsells J, OBrien JA, Melquist S, Soriano A, Zhang X, Ogawa A, Xu S, Joshi E, Della Rocca J, Hess FJ, Schachter J, Hesk D, Schenk D, Struyk A, Babaoglu K, Lohith TG, Wang Y, Yang K, Fu J, Evelhoch JL, Coleman PJ. Walji AM, et al. J Med Chem. 2016 May 26;59(10):4778-89. doi: 10.1021/acs.jmedchem.6b00166. Epub 2016 May 5. J Med Chem. 2016. PMID: 27088900
In vivo detection of NFTs using PET imaging represents a unique opportunity to develop a pharmacodynamic tool to accelerate the discovery of new disease modifying therapeutics targeting tau pathology. Herein, we present the discovery of 6-(fluoro-(18)F)-3-(1H-pyrrolo[2,3-c …
In vivo detection of NFTs using PET imaging represents a unique opportunity to develop a pharmacodynamic tool to accelerate the discovery of …
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ, Meng X, McQuade P, Klimas M, Getty K, Lin SA, Connolly BM, O'Malley SS, Haley H, Purcell M, Gantert L, Holahan M, Lindgren J, Eklund P, Ekblad C, Frejd FY, Hostetler ED, González Trotter DE, Evelhoch JL. Rubins DJ, et al. Mol Imaging Biol. 2021 Apr;23(2):241-249. doi: 10.1007/s11307-020-01544-2. Epub 2020 Oct 23. Mol Imaging Biol. 2021. PMID: 33098025
PROCEDURES: Z(PD-L1_4) was conjugated with NOTA and radiolabeled with either [(18)F]AlF or (68)Ga. [(18)F]AlF-NOTA-Z(PD-L1_4) and [(68)Ga]NOTA-Z(PD-L1_4) were evaluated in immunocompromised mice with LOX (PD-L1+) and SUDHL6 (PD-L1-) tumors with PET and ex vivo biodi …
PROCEDURES: Z(PD-L1_4) was conjugated with NOTA and radiolabeled with either [(18)F]AlF or (68)Ga. [(18)F]AlF-NOTA-Z(PD-L1_4) …
Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.
Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Haley H, Holahan M, Purcell M, Riffel K, Lohith TG, Coleman P, Soriano A, Ogawa A, Xu S, Zhang X, Joshi E, Della Rocca J, Hesk D, Schenk DJ, Evelhoch JL. Hostetler ED, et al. J Nucl Med. 2016 Oct;57(10):1599-1606. doi: 10.2967/jnumed.115.171678. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230925 Free article.
The (18)F-MK-6240 volume of distribution stabilized rapidly, indicating favorable tracer kinetics. ...Moderate defluorination was observed as skull uptake. CONCLUSION: (18)F-MK-6240 is a promising PET tracer for the in vivo quantification of NFTs in AD patients....
The (18)F-MK-6240 volume of distribution stabilized rapidly, indicating favorable tracer kinetics. ...Moderate defluorination was obs …
Measured dose rate constant from oncology patients administered 18F for positron emission tomography.
Quinn B, Holahan B, Aime J, Humm J, St Germain J, Dauer LT. Quinn B, et al. Med Phys. 2012 Oct;39(10):6071-9. doi: 10.1118/1.4749966. Med Phys. 2012. PMID: 23039646
This study reports exposure rates measured at various locations near positron emission tomography (PET) (18)F-FDG patients prior to PET scanning. These measurements are normalized for the amount of administered activity, measurement distance, and time postinjection and are …
This study reports exposure rates measured at various locations near positron emission tomography (PET) (18)F-FDG patients prior to P …
Negative and positive components of psychological masculinity and femininity and their relationships to self-reports of neurotic and acting out behaviors.
Spence JT, Helmreich RL, Holahan CK. Spence JT, et al. J Pers Soc Psychol. 1979 Oct;37(10):1673-82. J Pers Soc Psychol. 1979. PMID: 512834
Negatively valued masculinity (M-) and femininity (F-) personality scales were developed to supplement the positively valued Masculinity (M+) and Femininity (F+) scales of the Personal Attributes Questionnaire (PAQ; Spence & Helmreich). ...Scores on a self-estee …
Negatively valued masculinity (M-) and femininity (F-) personality scales were developed to supplement the positively valued Masculin …
9-hydroxyazafluorenes and their use in thrombin inhibitors.
Stauffer KJ, Williams PD, Selnick HG, Nantermet PG, Newton CL, Homnick CF, Zrada MM, Lewis SD, Lucas BJ, Krueger JA, Pietrak BL, Lyle EA, Singh R, Miller-Stein C, White RB, Wong B, Wallace AA, Sitko GR, Cook JJ, Holahan MA, Stranieri-Michener M, Leonard YM, Lynch JJ Jr, McMasters DR, Yan Y. Stauffer KJ, et al. J Med Chem. 2005 Apr 7;48(7):2282-93. doi: 10.1021/jm049423s. J Med Chem. 2005. PMID: 15801822
Optimization of a previously reported thrombin inhibitor, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-trans-4-aminocyclohexylmethylamide (1), by replacing the aminocyclohexyl P1 group provided a new lead structure, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylami …
Optimization of a previously reported thrombin inhibitor, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-trans-4-aminocyclohexylmethylamide (1), by …